Login Register Cart 0
Generic placeholder image

Current Cardiology Reviews

Editor-in-Chief

ISSN (Print): 1573-403X
ISSN (Online): 1875-6557

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Aldosterone Effect on Cardiac Structure and Function

Author(s): Ekhlas Mahmoud Al-Hashedi* and Fuad A. Abdu

Volume 20, Issue 4, 2024

Published on: 29 February, 2024

Article ID: e290224227534 Pages: 8

DOI: 10.2174/011573403X281390240219063817

Price: $65

Abstract

Background: Cardiac remodelling could be a key mechanism in aldosteronemediated cardiovascular morbidity and mortality. Experimental and clinical evidence has demonstrated that aldosterone causes cardiac structural remodelling and dysfunction by its profibrotic and pro-hypertrophic effects, which result mainly from the direct effects on myocardial collagen deposition, inflammation, and oxidative stress. Clinical studies have investigated the aldosterone effects on the heart in different clinical conditions, including general population, essential hypertension, primary aldosteronism, heart failure, and atrial fibrillation. Robust findings indicate that aldosterone or the activation of the cardiac mineralocorticoid receptor can cause damage to myocardial tissue by mechanisms independent of the blood pressure, leading to tissue hypertrophy, fibrosis, and dysfunction.

Conclusion: Aldosterone-mediated cardiovascular morbidity and mortality mainly result from cardiac structural and functional alterations. In different clinical settings, aldosterone can induce cardiac structural remodelling and dysfunction via several pathological mechanisms, including cardiac fibrosis, inflammation, and oxidative stress. Aldosterone antagonists could effectively decrease or reverse the detrimental aldosterone-mediated changes in the heart.

Graphical Abstract

[1]
Jaisser F, Farman N. Emerging roles of the mineralocorticoid receptor in pathology: Toward new paradigms in clinical pharmacology. Pharmacol Rev 2016; 68(1): 49-75.
[http://dx.doi.org/10.1124/pr.115.011106] [PMID: 26668301]
[2]
Catena C, Colussi G, Marzano L, Sechi L. Aldosterone and the heart: From basic research to clinical evidence. Horm Metab Res 2012; 44(3): 181-7.
[http://dx.doi.org/10.1055/s-0031-1291318] [PMID: 22095099]
[3]
Silvestre JS, Robert V, Heymes C, et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 1998; 273(9): 4883-91.
[http://dx.doi.org/10.1074/jbc.273.9.4883] [PMID: 9478930]
[4]
Struthers AD. Aldosterone blockade in cardiovascular disease. Heart 2004; 90(10): 1229-34.
[http://dx.doi.org/10.1136/hrt.2003.025312] [PMID: 15367532]
[5]
Funder JW. Aldosterone action. Annu Rev Physiol 1993; 55(1): 115-30.
[http://dx.doi.org/10.1146/annurev.ph.55.030193.000555] [PMID: 8466169]
[6]
Jorde UP, Vittorio T, Katz SD, Colombo PC, Latif F, Le Jemtel THJC. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation 2002; 106(9): 1055-7.
[7]
Pitt B. Escape” of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy. Cardiovasc Drugs Ther 1995; 9(1): 145-9.
[8]
Sato A, Suzuki Y, Shibata H, Saruta TJHR. Plasma aldosterone concentrations are not related to the degree of angiotensin-converting enzyme inhibition in essential hypertensive patients. Hypertens Res 2000; 23(1): 25-31.
[9]
Clyne CD, Zhang Y, Slutsker L, Mathis JM, White PC, Rainey WE. Angiotensin II and potassium regulate human CYP11B2 transcription through common cis-elements. Mol Endocrinol 1997; 11(5): 638-49.
[http://dx.doi.org/10.1210/mend.11.5.9920] [PMID: 9139807]
[10]
Rapezzi C. Comparison of candesartan, enalapril and their combination in congestive heart failure. Ital Heart J Suppl 2000; 1(3): 429-30.
[PMID: 10815278]
[11]
Grandi AM, Imperiale D, Santillo R, et al. Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension 2002; 40(5): 647-52.
[12]
Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E–left ventricular hypertrophy study. Circulation 2003; 108(15): 1831-8.
[13]
Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341(10): 709-17.
[14]
Sztechman D, Czarzasta K, Cudnoch-Jedrzejewska A, Szczepanska-Sadowska E, Zera T. Aldosterone and mineralocorticoid receptors in regulation of the cardiovascular system and pathological remodelling of the heart and arteries. J Physiol Pharmacol 2018; 69(6)
[http://dx.doi.org/10.26402/jpp.2018.6.01] [PMID: 30898981]
[15]
Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992; 120(6): 893-901.
[PMID: 1453111]
[16]
Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 71(3): A12-6.
[http://dx.doi.org/10.1016/0002-9149(93)90239-9] [PMID: 8421998]
[17]
Muiesan ML, Salvetti M, Paini A, et al. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension 2008; 52(3): 529-34.
[18]
Wu T, Ren Y, Wang W, et al. Left ventricular remodeling in patients with primary aldosteronism: A prospective cardiac magnetic resonance imaging study. Korean J Radiol 2021; 22(10): 1619.
[19]
Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, März W. Plasma aldosterone levels are associated with increased cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J 2010; 31(10): 1237-47.
[http://dx.doi.org/10.1093/eurheartj/ehq019] [PMID: 20200015]
[20]
Delles C, Schmidt BMW, Müller HJ, Oehmer S, Klingbeil AU, Schmieder RE. Functional relevance of aldosterone for the determination of left ventricular mass. Am J Cardiol 2003; 91(3): 297-301.
[http://dx.doi.org/10.1016/S0002-9149(02)03158-2] [PMID: 12565086]
[21]
Edelmann F, Tomaschitz A, Wachter R, et al. Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. Eur Heart J 2012; 33(2): 203-12.
[http://dx.doi.org/10.1093/eurheartj/ehr292] [PMID: 21856682]
[22]
Velagaleti RS, Gona P, Levy D, et al. Relations of biomarkers representing distinct biological pathways to left ventricular geometry. Circulation 2008; 118(22): 2252-2258/.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.108.817411] [PMID: 19001021]
[23]
Vasan RS, Evans JC, Benjamin EJ, et al. Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study. Hypertension 2004; 43(5): 957-62.
[http://dx.doi.org/10.1161/01.HYP.0000124251.06056.8e] [PMID: 15007028]
[24]
Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000; 15(4): 264-72.
[http://dx.doi.org/10.1097/00001573-200007000-00010] [PMID: 11139090]
[25]
Müller-Brunotte R, Kahan T, López B, et al. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: Results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA). J Hypertens 2007; 25(9): 1958-66.
[http://dx.doi.org/10.1097/HJH.0b013e3282170ada] [PMID: 17762662]
[26]
Al~Hashedi EM, Zhao X, Mohammed AA, Juvenal H. Serum aldosterone effect on left ventricular structure and diastolic function in essential hypertension. J Clin Hypertens 2023; 25(2): 213-22.
[27]
Catena C, Verheyen N, Pilz S, et al. Plasma aldosterone and left ventricular diastolic function in treatment-naïve patients with hypertension: tissue-Doppler imaging study. Hypertension 2015; 65(6): 1231-7.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.115.05285] [PMID: 25801873]
[28]
Nakahara T, Takata Y, Hirayama Y, et al. Left ventricular hypertrophy and geometry in untreated essential hypertension is associated with blood levels of aldosterone and procollagen type III amino-terminal peptide. Circ J 2007; 71(5): 716-21.
[http://dx.doi.org/10.1253/circj.71.716] [PMID: 17456997]
[29]
Fagard RH, Lijnen PJ, Petrov VV. Opposite associations of circulating aldosterone and atrial natriuretic peptide with left ventricular diastolic function in essential hypertension. J Hum Hypertens 1998; 12(3): 195-202.
[http://dx.doi.org/10.1038/sj.jhh.1000590] [PMID: 9579770]
[30]
Park SM, Kim MN, Kim S, Shim WJ. Serum aldosterone is related to left ventricular geometry and function in young adults with never-treated primary hypertension. J Clin Med 2019; 8(7): 1045.
[http://dx.doi.org/10.3390/jcm8071045] [PMID: 31319630]
[31]
Sechi LA, Novello M, Colussi G, et al. Relationship of plasma renin with a prothrombotic state in hypertension: Relevance for organ damage. Am J Hypertens 2008; 21(12): 1347-53.
[http://dx.doi.org/10.1038/ajh.2008.293] [PMID: 18948960]
[32]
Catena C, Colussi G, Valeri M, Sechi LA. Association of aldosterone with left ventricular mass in hypertension: Interaction with plasma fibrinogen levels. Am J Hypertens 2013; 26(1): 111-7.
[http://dx.doi.org/10.1093/ajh/hps006] [PMID: 23382334]
[33]
Mulè G, Nardi E, Cusimano P, et al. Plasma aldosterone and its relationships with left ventricular mass in essential hypertensive patients with the metabolic syndrome. Am J Hypertens 2008; 21(9): 1055-61.
[http://dx.doi.org/10.1038/ajh.2008.225] [PMID: 18583983]
[34]
Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: A systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018; 6(1): 41-50.
[35]
Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93(9): 3266-81.
[http://dx.doi.org/10.1210/jc.2008-0104] [PMID: 18552288]
[36]
Tsai CH, Pan CT, Chang YY, et al. Left ventricular remodeling and dysfunction in primary aldosteronism. J Hum Hypertens 2021; 35(2): 131-47.
[http://dx.doi.org/10.1038/s41371-020-00426-y] [PMID: 33067554]
[37]
Chang YY, Lee HH, Hung CS, et al. Association between urine aldosterone and diastolic function in patients with primary aldosteronism and essential hypertension. Clin Biochem 2014; 47(13-14): 1329-32.
[38]
Yang Y, Zhu LM, Xu JZ, Tang XF, Gao PJ. Comparison of left ventricular structure and function in primary aldosteronism and essential hypertension by echocardiography. Hypertens Res 2017; 40(3): 243-50.
[39]
Boulestreau R, Cremer A, Delarche N, Gosse P. Alteration of left ventricular longitudinal systolic function in 2D-strain in primary aldosteronism: A new target organ damage marker. Ann Cardiol Angeiol 2018; 67(5): 315-20.
[http://dx.doi.org/10.1016/j.ancard.2018.08.007] [PMID: 30327134]
[40]
Catena C, Colussi G, Novello M, et al. Dietary salt intake is a determinant of cardiac changes after treatment of primary aldosteronism: A prospective study. Hypertension 2016; 68(1): 204-12.
[41]
Pimenta E, Gordon RD, Ahmed AH, et al. Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: Results of a case-control study. J Clin Endocrinol Metab 2011; 96(9): 2813-20.
[http://dx.doi.org/10.1210/jc.2011-0354] [PMID: 21632817]
[42]
Stowasser M, Sharman J, Leano R, et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 2005; 90(9): 5070-6.
[http://dx.doi.org/10.1210/jc.2005-0681] [PMID: 15941863]
[43]
Hung CS, Chou CH, Liao CW, et al. Aldosterone induces tissue inhibitor of metalloproteinases-1 expression and further contributes to collagen accumulation: From clinical to bench studies. Hypertension 2016; 67(6): 1309-20.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.115.06768] [PMID: 27113051]
[44]
Hung CS, Chou CH, Wu XM, et al. Circulating tissue inhibitor of matrix metalloproteinase-1 is associated with aldosterone-induced diastolic dysfunction. J Hypertens 2015; 33(9): 1922-30.
[http://dx.doi.org/10.1097/HJH.0000000000000619] [PMID: 26103125]
[45]
Rossi GP, Cesari M, Cuspidi C, et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 2013; 62(1): 62-9.
[46]
Pan CT, Wu XM, Tsai CH, et al. Hemodynamic and non-hemodynamic components of cardiac remodeling in primary aldosteronism. Front Endocrinol 2021; 12646097
[http://dx.doi.org/10.3389/fendo.2021.646097] [PMID: 33953695]
[47]
Cuspidi C, Tadic M, Sala C, et al. Regression of left ventricular hypertrophy in primary aldosteronism after adrenalectomy: A meta-analysis of echocardiographic studies. J Hypertens 2021; 39(4): 775-83.
[http://dx.doi.org/10.1097/HJH.0000000000002679] [PMID: 33044383]
[48]
Catena C, Colussi G, Lapenna R, et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50(5): 911-8.
[49]
Cicala M, Cesari M, Patalano A, Iacobone M, Mariniello B. Treatment of primary aldosteronism: Short and middle-term effects of medical and surgical therapy in primary hyperaldosteronism. experience on 45 cases: PP.18.187. J Hypertens 2010; 28e305
[50]
Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82(5): 1724-9.
[http://dx.doi.org/10.1161/01.CIR.82.5.1724] [PMID: 2146040]
[51]
Girerd N, Pang PS, Swedberg K, et al. Serum aldosterone is associated with mortality and re‐hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: Analysis from the EVEREST trial. Eur J Heart Fail 2013; 15(11): 1228-35.
[http://dx.doi.org/10.1093/eurjhf/hft100] [PMID: 23787720]
[52]
Weber KTJNEJM. Aldosterone in congestive heart failure. N Engl J Med 2001; 345(23): 1689-97.
[53]
Braunwald E. Heart failure. JACC Heart Fail 2013; 1(1): 1-20.
[http://dx.doi.org/10.1016/j.jchf.2012.10.002] [PMID: 24621794]
[54]
Löfsjögård J, Kahan T, Díez J, et al. Biomarkers of collagen type I metabolism are related to B-type natriuretic peptide, left ventricular size, and diastolic function in heart failure. J Cardiovasc Med 2014; 15(6): 463-9.
[http://dx.doi.org/10.2459/01.JCM.0000435617.86180.0b] [PMID: 24983265]
[55]
Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348(14): 1309-21.
[http://dx.doi.org/10.1056/NEJMoa030207] [PMID: 12668699]
[56]
Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364(1): 11-21.
[http://dx.doi.org/10.1056/NEJMoa1009492] [PMID: 21073363]
[57]
Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J 2016; 37(27): 2105-14.
[http://dx.doi.org/10.1093/eurheartj/ehw132] [PMID: 27130705]
[58]
Bozkurt B, Hershberger RE, Butler J, et al. 2021 ACC/AHA key data elements and definitions for heart failure. J Am Coll Cardiol 2021; 77(16): 2053-150.
[http://dx.doi.org/10.1016/j.jacc.2020.11.012] [PMID: 33250265]
[59]
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42(36): 3599-726.
[http://dx.doi.org/10.1093/eurheartj/ehab368] [PMID: 34447992]
[60]
Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ. Heart failure with preserved ejection fraction: From mechanisms to therapies. Eur Heart J 2018; 39(30): 2780-92.
[http://dx.doi.org/10.1093/eurheartj/ehy301] [PMID: 29905796]
[61]
Phan TT, Shivu GN, Abozguia K, Sanderson JE, Frenneaux M. The pathophysiology of heart failure with preserved ejection fraction: From molecular mechanisms to exercise haemodynamics. Int J Cardiol 2012; 158(3): 337-43.
[http://dx.doi.org/10.1016/j.ijcard.2011.06.113] [PMID: 21794933]
[62]
Su MYM, Lin LY, Tseng YHE, et al. CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF. JACC Cardiovasc Imaging 2014; 7(10): 991-7.
[http://dx.doi.org/10.1016/j.jcmg.2014.04.022] [PMID: 25240451]
[63]
Ke B, Tan X, Ren L, et al. Aldosterone dysregulation predicts the risk of mortality and rehospitalization in heart failure with a preserved ejection fraction. Sci China Life Sci 2022; 65(3): 631-42.
[http://dx.doi.org/10.1007/s11427-021-1945-6] [PMID: 34258711]
[64]
Deswal A, Richardson P, Bozkurt B, Mann DL. Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF). J Card Fail 2011; 17(8): 634-42.
[http://dx.doi.org/10.1016/j.cardfail.2011.04.007] [PMID: 21807324]
[65]
Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo-DHF randomized controlled trial. JAMA 2013; 309(8): 781-91.
[http://dx.doi.org/10.1001/jama.2013.905] [PMID: 23443441]
[66]
Xiang Y, Shi W, Li Z, et al. Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction. Medicine 2019; 98(13)e14967
[http://dx.doi.org/10.1097/MD.0000000000014967] [PMID: 30921200]
[67]
Chen Y, Wang H, Lu Y, Huang X, Liao Y, Bin J. Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: A meta-analysis of randomized clinical trials. BMC Med 2015; 13(1): 10.
[http://dx.doi.org/10.1186/s12916-014-0261-8] [PMID: 25598008]
[68]
Desai AS, Lewis EF, Li R, et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 2011; 162(6): 966-972.e10.
[http://dx.doi.org/10.1016/j.ahj.2011.09.007] [PMID: 22137068]
[69]
Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370(15): 1383-92.
[http://dx.doi.org/10.1056/NEJMoa1313731] [PMID: 24716680]
[70]
Beygui F, Cayla G, Roule V, et al. Early aldosterone blockade in acute myocardial infarction. J Am Coll Cardiol 2016; 67(16): 1917-27.
[http://dx.doi.org/10.1016/j.jacc.2016.02.033] [PMID: 27102506]
[71]
Ennis IL, Pérez NG. Cardiac mineralocorticoid receptor and the Na+/H+ exchanger: Spilling the beans. Front Cardiovasc Med 2021; 7614279
[http://dx.doi.org/10.3389/fcvm.2020.614279] [PMID: 33553262]
[72]
Bristow MR, Silva Enciso J, Gersh BJ, et al. Detection and management of geographic disparities in the TOPCAT Trial. JACC Basic Transl Sci 2016; 1(3): 180-9.
[http://dx.doi.org/10.1016/j.jacbts.2016.03.001] [PMID: 27747305]
[73]
Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of atrial fibrillation: Relationships among clinical features, epidemiology, and mechanisms. Circ Res 2014; 114(9): 1453-68.
[http://dx.doi.org/10.1161/CIRCRESAHA.114.303211] [PMID: 24763464]
[74]
Goette A, Hoffmanns P, Enayati W, Meltendorf U, Geller JC, Klein HU. Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol 2001; 88(8): 906-90909, a908 d.
[http://dx.doi.org/10.1016/S0002-9149(01)01905-1]
[75]
Tsai CT, Chiang FT, Tseng CD, et al. Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol 2010; 55(8): 758-70.
[http://dx.doi.org/10.1016/j.jacc.2009.09.045] [PMID: 20170814]
[76]
Watson T, Karthikeyan VJ, Lip GY. Atrial fibrillation in primary aldosteronism. Horm Metab Res 2009; 10(4): 190-4.
[77]
Reil JC, Hohl M, Selejan S, et al. Aldosterone promotes atrial fibrillation. Eur Heart J 2012; 33(16): 2098-108.
[http://dx.doi.org/10.1093/eurheartj/ehr266] [PMID: 21816854]
[78]
Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 2001; 37(7): 1800-7.
[http://dx.doi.org/10.1016/S0735-1097(01)01243-8] [PMID: 11401114]
[79]
Mayyas F, Alzoubi KH, Van Wagoner DR. Impact of aldosterone antagonists on the substrate for atrial fibrillation: Aldosterone promotes oxidative stress and atrial structural/electrical remodeling. Int J Cardiol 2013; 168(6): 5135-42.
[http://dx.doi.org/10.1016/j.ijcard.2013.08.022] [PMID: 23993726]
[80]
Rossi GP, Bolognesi M, Rizzoni D, et al. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension 2008; 51(5): 1366-71.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.108.111369] [PMID: 18347224]
[81]
Seccia TM, Caroccia B, Adler GK, Maiolino G, Cesari M, Rossi GP. Arterial hypertension, atrial fibrillation, and hyperaldosteronism. Hypertension 2017; 69(4): 545-50.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.116.08956] [PMID: 28264920]
[82]
Alexandre J, Hof T, Puddu PE, et al. Rapid and MR-independent IK1 activation by aldosterone during ischemia-reperfusion. PLoS One 2015; 10(7)e0132592
[http://dx.doi.org/10.1371/journal.pone.0132592] [PMID: 26222262]
[83]
Alexandre J, Puddu PE, Simard C, et al. Proarrhythmic effects of aldosterone during myocardial ischemia-reperfusion: Implication of the sarcolemmal-KATP channels. J Cardiovasc Pharmacol 2014; 64(2): 134-41.
[http://dx.doi.org/10.1097/FJC.0000000000000097] [PMID: 24662493]
[84]
Ouvrard-Pascaud A, Sainte-Marie Y, Bénitah JP, et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 2005; 111(23): 3025-33.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.104.503706] [PMID: 15939817]
[85]
Lammers C, Dartsch T, Brandt MC, et al. Spironolactone prevents aldosterone induced increased duration of atrial fibrillation in rat. Cell Physiol Biochem 2012; 29(5-6): 833-40.
[http://dx.doi.org/10.1159/000178483] [PMID: 22613983]
[86]
Alexandre J, Sezai A, Allouche S, et al. Aldoscore to predict postoperative atrial fibrillation after cardiac surgery. J Hypertens 2017; 35(10): 2115-6.
[http://dx.doi.org/10.1097/HJH.0000000000001470] [PMID: 28858201]
[87]
Seccia TM, Letizia C, Muiesan ML, et al. Atrial fibrillation as presenting sign of primary aldosteronism: Results of the prospective appraisal on the prevalence of primary aldosteronism in hypertensive (PAPPHY) study. J Hypertens 2020; 38(2): 332-9.
[http://dx.doi.org/10.1097/HJH.0000000000002250] [PMID: 31834121]
[88]
Liu T, Korantzopoulos P, Shao Q, Zhang Z, Letsas KP, Li G. Mineralocorticoid receptor antagonists and atrial fibrillation: A meta-analysis. Europace 2016; 18(5): 672-8.
[http://dx.doi.org/10.1093/europace/euv366] [PMID: 26705563]
[89]
Neefs J, van den Berg NWE, Limpens J, et al. Aldosterone pathway blockade to prevent atrial fibrillation: A systematic review and meta-analysis. Int J Cardiol 2017; 231: 155-61.
[http://dx.doi.org/10.1016/j.ijcard.2016.12.029] [PMID: 28062142]
[90]
Wang W, Chen Q, Zhang F, et al. Radiofrequency catheter ablation combined with spironolactone in the treatment of atrial fibrillation: A single-center randomized controlled study. Clin Cardiol 2021; 44(8): 1120-7.
[http://dx.doi.org/10.1002/clc.23659] [PMID: 34076288]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy